Objective: The purpose of this study was to investigate potential relationships between cerebrospinal fluid (CSF) measurements of beta-amyloid 1-42 (Aβ42) and total tau with [ 
Introduction
At present, there are two promising methods for in vivo assessment of the extent of Alzheimer's disease (AD) pathology. One is the use of cerebrospinal fluid (CSF) biomarkers of betaamyloid-1-42 (Aβ42) and tau, the other imaging of neuropathology associated with AD using positron emission tomography (PET) and [ , (2) . Biochemical changes in CSF (decrease of Aβ42 and increase of tau) are thought to indirectly reflect the presence of AD pathology (3) . Imaging using either [ Although it is generally accepted that both types of markers (i.e. CSF and PET) reflect amyloid and/or tau load, the relationship between these two types of biomarkers has not been studied extensively. Only a few studies have investigated the relationship between [ 11 C]PIB and CSF measurements. Studies were performed in groups mainly consisting of healthy controls (8 , 9) or patients with mild cognitive impairment (MCI) (10 , 11) and recently in a group consisting solely of AD patients (12) . In these studies an inverse relationship between [ 11 C]PIB and CSF Aβ42 levels was found, but either no (8) or only a modest (10) between global cortical binding of both tracers suggested that they measured related, but different aspects of the neuropathology associated with AD. The purpose of the present study was to investigate potential relationships between CSF measurements of Aβ42 and tau, and PET measurements using [ neurological examinations, laboratory tests, brain magnetic resonance imaging (MRI), and extensive neuropsychological testing. Clinical diagnosis was established by consensus in a multidisciplinary team, without knowledge of PET and CSF data. All AD patients met NINCDS-ADRDA criteria for "probable AD" (14) . MCI patients met Petersen criteria based on subjective and objective cognitive impairment, predominantly affecting memory, in the absence of dementia or significant functional loss (15) . Control subjects were recruited through advertisements in newspapers and underwent the same diagnostic procedures. Exclusion criteria were history of major psychiatric or neurological (other than AD) illness and use of non-steroidal antiinflammatory drugs (NSAIDS), as these have been reported to compete with [ 18 F]FDDNP for binding to Aβ fibrils in vitro and to Aβ plaques ex vivo (16) . Additional exclusion criteria for controls were: subjective memory complaints or clinically significant abnormalities on the MRI scan (as determined by a neuroradiologist). Written informed consent was obtained from all subjects after a complete written and verbal description of the study. The study was approved by the Medical Ethics Review Committee of the VU University Medical Centre Amsterdam.
Positron emission tomography
PET scans were performed on an ECAT EXACT HR+ scanner (Siemens/CTI, Knoxville, USA), equipped with a neuro-insert. This scanner enables the acquisition of 63 transaxial planes over a 15.5 cm axial FOV, thus allowing the whole brain to be imaged in a single bed position. The properties of this scanner have been reported previously (17) . All subjects received a venous cannula for tracer injection. Patient motion was restricted by the use of a head holder and monitored using laser beams. First, a 10 minutes transmission scan was performed in 2D acquisition mode using three retractable rotating line sources to correct the subsequent emission scan for photon attenuation. Next, a dynamic emission scan in 3D acquisition mode was started simultaneously with the intravenous injection of 354±74 MBq [ 11 C]PIB with a specific activity (SA) of 43±25 GBq/µmol using an infusion pump (Med-Rad, Beek, the Netherlands) followed by a flush of saline, at a rate of 0.8 mL/sec for the first 5 mL and 2.0 mL/ sec thereafter. Radiolabeled [ 11 C]PIB was synthesised according to a modification (18) of the procedure described by Wilson et al (19) . The dynamic emission scan consisted of 23 frames with progressive increase in frame duration (1x15, 3x5, 3x10, 2x30, 3x60, 2x150, 2x300, 7x600 s) for a total duration of 90 minutes. Finally, after a resting period of at least 1 hour to allow for decay of 
Magnetic resonance imaging
All subjects underwent a structural MRI scan using a Siemens 1.5 T Sonata scanner (Siemens Medical Solutions, Erlangen, Germany). The scan protocol included a coronal T1-weighted 3D MPRAGE (magnetization prepared rapid acquisition gradient echo; slice thickness 1.5 mm, 160 slices; matrix size 256x256; voxel size 1x1x1.5 mm; echo time=3.97 ms; repetition time=2700 ms; inversion time=950 ms; flip angle 8°), which was used for co-registration and region of interest (ROI) definition.
Image analysis
All PET sinograms were corrected for dead time, tissue attenuation using the transmission scan, decay, scatter and randoms, and were reconstructed using a standard filtered back projection algorithm and a Hanning filter with a cut-off at 0.5 times the Nyquist frequency. A zoom factor of 2 and a matrix size of 256×256×63 were used, resulting in a voxel size of 1.2×1.2×2.4 mm and a spatial resolution of approximately 7mm full-width at half-maximum at the centre of the field of view. MRI images were aligned to corresponding PET images using a mutual information algorithm (21) . Data were further analysed using PVE lab, a software program that uses a previously validated probability-map of 35 delineated ROIs (22) . No correction for partial volume effects was applied to the PET data. ROIs were projected onto [ These parametric images were generated by applying a basis function implementation of the "two-step" simplified reference tissue model with cerebellar grey matter as reference tissue (RPM2) (23) to the full dynamic 90 minutes PET data. Recently, RPM2 has been identified as the quantitative method of choice for both tracers (24 , 25) . BP ND is a quantitative measure of specific binding, reflecting the concentration of specifically bound tracer relative to the concentration of free and non-specifically bound tracer in tissue under equilibrium conditions (26) . All ROIs, including cerebellum, and their corresponding grey matter volumes were obtained using PVE lab (22) . For regional analyses, BP ND of frontal (volume weighted average of orbital frontal, medial inferior frontal and superior frontal), parietal and temporal (volume weighted average of superior temporal and medial inferior temporal) cortex and medial temporal lobe (MTL) (volume weighted average of enthorinal cortex and hippocampus) and posterior cingulate was used. In addition, a global cortical ROI was defined, based on the volume weighted average of all aforementioned regions. Cerebellar grey matter was chosen as reference tissue because of its (histopathological) lack of Congo red and thioflavin-S-positive plaques (27 , 28) .
Cerebrospinal fluid
CSF was obtained by lumbar puncture (LP) between L3/L4 or L4/L5 intervertebral spaces, using a 25-gauge needle, and collected in 10 mL polypropylene tubes. Within 2 hours, CSF samples were centrifuged at 1800 g for 10 minutes at 4 °C. A small amount of CSF was used for routine analysis, including total cells (leucocytes and erythrocytes), total protein and glucose. CSF was aliquoted in polypropylene tubes of 0.5 or 1 mL, and stored at −80 °C until further analysis. CSF Aβ42 and tau were measured with Innotest (Innogenetics, Ghent, Belgium) sandwich ELISA as described previously (29). As the manufacturer does not supply control data, performance of the assays was monitored using pools of surplus CSF specimens. In the study period multiple specimens with various concentrations, which were included in 7-18 runs, were used for this purpose. The mean coefficients of variation (±SD) obtained were 11.3±4.9% for Aβ42 and 9.3±1.5% for tau. Median time from LP to PET was 3 months (interquartile range 6 months). Five subjects (2 AD patients, 1 MCI patient and 2 controls) received their LP more than 12 months apart from (before) the PET scan. After exclusion of these subjects median time from LP to PET was 2.5 months.
Statistical analysis
Data are presented as mean±SD, unless otherwise stated. As CSF biomarker levels were not normally distributed, data were log-transformed. Frequency distributions for sex were compared with Chi-squared tests. For continuous measures, differences between groups were assessed using analysis of variance (ANOVA) with post-hoc least significant difference (LSD) tests and age as covariate. For assessment of relationships between CSF and BP ND data, first Pearson's correlations were calculated across the entire group. Next, linear regression analyses were performed to adjust for potential confounders using CSF biomarkers as independent and global and regional BP ND as dependent variable. Separate analyses were performed for [ In the first model, the relationship of each CSF biomarker with both PET tracers was adjusted for grey matter ROI volume. In the second model, analyses were additionally adjusted for age, sex and diagnosis (using dummy variables). In the third model, CSF biomarkers were entered simultaneously, together with the same covariates. This analysis was repeated after exclusion of the 5 subjects with long intervals between LP and PET. Standardised β's are reported to allow comparison of effect sizes. A p value below 0.05 was considered significant.
Results
Demographic and clinical data by patient group are presented in Table 1 . The three groups were similar with respect to sex. AD patients tended to be younger than MCI patients and controls. AD patients had lower MMSE scores than control subjects and MCI patients (both p<0.001). Group differences were found for CSF levels of Aβ42 and tau (p≤0.001). In addition, groups differed with respect to global cortical [ Table 2 lists Pearson's correlations between Aβ42 and tau levels in CSF and global and regional tracer BP ND across all subjects. Lower Aβ42 and higher tau levels were associated with higher global [ 11 C]PIB binding (Figure 2 ). This was due to higher binding in all cortical regions investigated for Aβ42 and in all, except MTL, for tau. Furthermore, lower Aβ42 and higher tau levels were associated with higher global [ (Figure 3) . In this case, lower CSF Aβ42 was associated with higher uptake in frontal and parietal cortex, but there were no correlations with other brain regions investigated. Higher CSF levels of tau were associated with higher uptake in all regions, except MTL.
Next, linear regression analyses were performed to adjust for potential confounders. After adjustment for grey matter ROI volume (model 1), associations were observed between both CSF markers (i.e. low CSF Aβ42 and high CSF tau) and increased global and regional [ 
Discussion
In the present study relationships between two CSF biomarkers (Aβ42 and tau) and uptake of two PET amyloid tracers ([ ), MCI patients (10) or AD patients (12) . In the present study this relationship was extended to the entire spectrum of cognitive decline, providing further support for the notion that [ The lack of associations in this region may be due to technical reasons. This region, being the volume weighted average of entorhinal cortex and hippocampus, was relatively small, making it sensitive to noise. Furthermore, as MTL atrophy is commonly seen in AD (31), differences in MTL volumes between diagnostic groups may lead to partial volume effects and thus underestimation of the signal in AD patients. This potentially causes reduced variability in MTL BP ND between diagnostic groups and consequently a lack of association with CSF biomarkers. When linear regression analyses were performed with adjustment for grey matter ROI volume, a trend was found for high CSF levels of tau to be associated with increased [ 18 F]FDDNP binding in the MTL. After additional adjustment for age, sex and diagnosis, this trend disappeared, although the effect size remained strong. This suggests that indeed partial volume effects in the MTL have at least partly underestimated tracer binding in this region. However, PET data were not corrected for partial volume effects. The choice was made not to correct for partial voluming, as potential overcorrection may lead to an artificially high signal. This approach ascertains that any observed increase in binding is real, which is a deliberate conservative approach. But more importantly, current status of partial volume correction (PVC) in amyloid imaging is not clear. For [ 11 C]PIB studies, several PVC methods have been used, most commonly a method developed by Meltzer (32) and an algorithm implemented in the PMOD software package (PMOD Technologies Ltd., Adliswil, Switzerland). These methods are based on T1-weighted structural MR scans. However, a study performed by our group (33) showed that accuracy of MR based PVC depends greatly on MR scanner type, scanning sequence and gray/white matter segmentation algorithm. The results of that study indicate that accuracy of PVC should be further evaluated before it can be used in patient studies. ' The main strength of the present study is its unique design, performing CSF sampling and PET scanning with both ligands in the same subjects along the spectrum of cognitive decline. This enabled a direct assessment of the relationship between two types of biomarkers both aimed at identifying underlying AD pathology. Further research in tauopathies other than AD will be valuable in gaining more insight in the validity of [ 
